Kalakonda, Nagesh ; Maerevoet, Marie ; Cavallo, Federica ; Follows, George ; Goy, Andre ; Vermaat, Joost S P ; Casasnovas, Olivier ; Hamad, Nada ; Zijlstra, Josée M ; Bakhshi, Sameer ; Bouabdallah, Reda ; Choquet, Sylvain ; Gurion, Ronit ; Hill, Brian ; Jaeger, Ulrich ; Sancho, Juan Manuel ; Schuster, Michael ; Thieblemont, Catherine ; De la Cruz, Fátima ; Egyed, Miklos ; Mishra, Sourav ; Offner, Fritz ; Vassilakopoulos, Theodoros P ; Warzocha, Krzysztof ; McCarthy, Daniel ; Ma, Xiwen ; Corona, Kelly ; Saint-Martin, Jean-Richard ; Chang, Hua ; Landesman, Yosef ; Joshi, Anita ; Wang, Hongwei ; Shah, Jatin ; Shacham, Sharon ; Kauffman, Michael ; Van Den Neste, Eric ; Canales, Miguel A (2020) Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial The Lancet Haematology, 7 (7). e511-e522. ISSN 23523026
Full text not available from this repository.
Related URL: http://dx.doi.org/10.1016/S2352-3026(20)30120-4
Abstract
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear export, in patients with relapsed or refractory DLBCL who had no therapeutic options of potential clinical benefit.
| Item Type: | Article |
|---|---|
| Source: | Copyright of this article belongs to The Lancet Haematology. |
| ID Code: | 137202 |
| Deposited On: | 04 Aug 2025 05:23 |
| Last Modified: | 04 Aug 2025 05:23 |
Repository Staff Only: item control page
